GINET use is contraindicated in pregnancy. If pregnancy occurs during treatment with GINET, use should be immediately stopped. Embryotoxic or teratogenic effects have been investigated using the active ingredients in combination. Administration during organogenesis and before development of the external genitalia gave no indication of a general teratogenic effect. Signs of feminisation in male foetuses could occur following higher doses of cyproterone acetate during the hormone-sensitive differentiation phase of the genital organs (after day 45 of gestation). There were no signs of feminization in male newborn children who had been exposed in utero to cyproterone acetate. THANKS